ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

This study is ongoing, but not recruiting participants.

Sponsored by: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov Identifier: NCT00077974
  Purpose

To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma


Condition Intervention Phase
Carcinoma, Renal Cell
Drug: SU011248
Phase II

Drug Information available for:   Sunitinib    Sunitinib malate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title:   A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Objective response rate according to RECIST [ Time Frame: 4 yrs ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Other anti-tumor efficacy including progression-free survival, overall survival, and duration of response and safety [ Time Frame: 4 yrs ] [ Designated as safety issue: No ]

Enrollment:   106
Study Start Date:   February 2004
Estimated Study Completion Date:   October 2008
Estimated Primary Completion Date:   October 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Experimental Drug: SU011248
50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Cytokine refractory metastatic renal cell carcinoma with clear cell component
  • Radiographic evidence of disease progression during or within 9 months of completion of 1 cytokine therapy
  • Prior nephrectomy

Exclusion Criteria:

  • Prior treatment with any systemic therapy other than 1 cytokine therapy
  • History of or known brain metastases
  • Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study start
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00077974

Locations
United States, California
Pfizer Investigational Site    
      San Francisco, California, United States, 94115
Pfizer Investigational Site    
      Duarte, California, United States, 91010-3000
Pfizer Investigational Site    
      Pasadena, California, United States, 91105
United States, Massachusetts
Pfizer Investigational Site    
      Boston, Massachusetts, United States, 02114
Pfizer Investigational Site    
      Boston, Massachusetts, United States, 02115
Pfizer Investigational Site    
      Boston, Massachusetts, United States, 02215
United States, Michigan
Pfizer Investigational Site    
      ANN ARBOR, Michigan, United States, 48109
United States, Minnesota
Pfizer Investigational Site    
      Rochester, Minnesota, United States, 55905
United States, New York
Pfizer Investigational Site    
      NEW YORK, New York, United States, 10021
Pfizer Investigational Site    
      New York, New York, United States, 10022
United States, North Carolina
Pfizer Investigational Site    
      Durhan, North Carolina, United States, 27705
United States, Ohio
Pfizer Investigational Site    
      Cleveland, Ohio, United States, 44195
United States, Oregon
Pfizer Investigational Site    
      Portland, Oregon, United States, 97213
United States, Pennsylvania
Pfizer Investigational Site    
      Philadelphia, Pennsylvania, United States, 19111
United States, Wisconsin
Pfizer Investigational Site    
      Madison, Wisconsin, United States, 53792

Sponsors and Collaborators
Pfizer

Investigators
Study Director:     Pfizer CT.gov Call Center     Pfizer    
  More Information


To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site
 

Publications indexed to this study:

Responsible Party:   Pfizer Inc ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:   A6181006
First Received:   February 13, 2004
Last Updated:   November 21, 2008
ClinicalTrials.gov Identifier:   NCT00077974
Health Authority:   United States: Food and Drug Administration

Study placed in the following topic categories:
Urogenital Neoplasms
Renal cancer
Urologic Neoplasms
Kidney cancer
Carcinoma
Urologic Diseases
Kidney Neoplasms
Sunitinib
Carcinoma, Renal Cell
Kidney Diseases
Adenocarcinoma
Urinary tract neoplasm
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type
Antineoplastic Agents
Growth Substances
Therapeutic Uses
Physiological Effects of Drugs
Growth Inhibitors
Angiogenesis Modulating Agents
Angiogenesis Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers